Post hoc analyses were conducted to ( 1 ) examine patient characteristics of those eligible and ineligible for omalizumab , ( 2 ) describe onset of effect after initiation of omalizumab and offset of treatment effect after stopping therapy , and ( 3 ) determine whether the efficacy differs by age , asthma severity , dosing regimen , and prespecified biomarkers .